AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy ... Read More
Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More
Lantern Pharma gets FDA nod for LP-284 clinical trial in non-Hodgkin’s lymphoma
Lantern Pharma Inc. (NASDAQ: LTRN), a trailblazer in artificial intelligence (AI) and machine learning (ML) for targeted cancer therapies, has received clearance from the United ... Read More
Aurobindo Pharma subsidiary receives FDA approval for Plerixafor Injection
Eugia Pharma Specialities Limited, a fully-owned subsidiary of India-based Aurobindo Pharma Limited, has received final approval from the US Food and Drug Administration (FDA). This ... Read More